Tuesday, 9 August 2016

Toll Like Receptor 4 (CD284 or TLR4) - Pipeline Review, H1 2016

WiseGuyReports.Com Publish a New Market Research Report On –“Toll Like Receptor 4 (CD284 or TLR4) - Pipeline Review, H1 2016”.


The, ‘Toll Like Receptor 4 (CD284 or TLR4) - Pipeline Review, H1 2016’, provides in depth analysis on Toll Like Receptor 4 (CD284 or TLR4) targeted pipeline therapeutics.

The report provides comprehensive information on the Toll Like Receptor 4 (CD284 or TLR4), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Toll Like Receptor 4 (CD284 or TLR4) targeted therapeutics development and features dormant and discontinued projects.

For more information or any query mail at sales@wiseguyreports.com

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


Scope

- The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 4 (CD284 or TLR4)
- The report reviews Toll Like Receptor 4 (CD284 or TLR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Toll Like Receptor 4 (CD284 or TLR4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Toll Like Receptor 4 (CD284 or TLR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Toll Like Receptor 4 (CD284 or TLR4) targeted therapeutics

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Toll Like Receptor 4 (CD284 or TLR4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Toll Like Receptor 4 (CD284 or TLR4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table Of Contents – Key Points

List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Toll Like Receptor 4 (CD284 or TLR4) Overview 10
Therapeutics Development 11
Toll Like Receptor 4 (CD284 or TLR4) - Products under Development by Stage of Development 11
Toll Like Receptor 4 (CD284 or TLR4) - Products under Development by Therapy Area 12
Toll Like Receptor 4 (CD284 or TLR4) - Products under Development by Indication 13
Toll Like Receptor 4 (CD284 or TLR4) - Pipeline Products Glance 16
Late Stage Products 16
Early Stage Products 17
Toll Like Receptor 4 (CD284 or TLR4) - Products under Development by Companies 18
Toll Like Receptor 4 (CD284 or TLR4) - Products under Development by Universities/Institutes 23
Toll Like Receptor 4 (CD284 or TLR4) - Therapeutics Assessment 25
Assessment by Monotherapy/Combination Products 25
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Toll Like Receptor 4 (CD284 or TLR4) - Companies Involved in Therapeutics Development 32
Batu Biologics, Inc. 32
BioLineRx, Ltd. 33
Biomedica Management Corporation 34
Eisai Co., Ltd. 35
eTheRNA Immunotherapies NV 36
Formune S.L. 37
GlaxoSmithKline Plc 38
Harbor Therapeutics, Inc. 39
Immune Design Corp. 40
Immunovo BV 41
Kyorin Pharmaceutical Co., Ltd. 42
NovImmune SA 43
Reliance Life Sciences Pvt. Ltd. 44
TaiwanJ Pharmaceuticals Co., Ltd. 45
Vascular Biogenics Ltd. 46
Toll Like Receptor 4 (CD284 or TLR4) - Drug Profiles 47
ApTLR-4FT - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
BL-1110 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
C-34 - Drug Profile 50
Product Description 50 
Continue……

For more information or any query mail at sales@wiseguyreports.com


Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)

No comments:

Post a Comment